Case studies

SolidBiogen

Solid Biosciences is a life science company, founded in 2014 and focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those directly impacted by the disease, Solid aims to be the center of excellence across the entire DMD disease spectrum, bringing together people with expertise in science, technology, and healthcare to drive forward a portfolio of candidates with life-changing potential.

Solid GT, a subsidiary of Solid Biosciences, is focused on developing novel genetic interventions with the potential to slow or even halt the progression of DMD. Solid GT’s lead candidate, SGT-001, is an adeno-associated viral (AAV) vector-mediated gene therapy. This therapy is being investigated in IND-enabling studies for the potential to drive expression of micro-dystrophin, a shorter form of the dystrophin protein fundamental for muscle function and missing in patients with DMD.


Solid Biosciences became interested in Atlas5D’s technology, Echo5D, for high-precision, 24x7 real-world measurement of movement, particularly in how the technology could provide objective evidence of mobility change in a pediatric population. Atlas5D began working with Solid Biosciences in 2016 to help children and families affected by DMD.

“We believe that, for the first time, Echo5D may provide us with the ability to objectively measure real-world mobility in boys affected with DMD. The prospect of non-invasive metrics for patients performing common, everyday activities in daily life at home represents a tremendous opportunity to learn about the real-world impact of our therapeutic interventions. We are excited that this collaboration may help guide our efforts to find a treatment for this devastating disease.”

Jorge Quiroz, MD, MBA

Chief Medical Officer, Solid GT

 


 

Biogen is one of the world’s leading biotechnology companies, with a focus on developing therapies for neurodegenerative, hematologic and autoimmune disorders. Founded in 1978, Biogen’s work in biologics and small-molecule drug discovery has led to the world’s most extensive portfolio of multiple sclerosis (MS) therapies and innovative new treatments for hemophilia patients.

Biogen seeks to enhance individualized treatment outcomes through emerging technology, clinical innovation, and continuous learning. Biogen’s work aims to capitalize on new and emerging technology to collect and better synthesize information in order to improve knowledge of disease impacts and therapies.


Biogen became interested in Atlas5D’s technology, Echo5D, for high-precision, 24x7 real-world measurement of movement — particularly in how the technology could be applied to MS, an autoimmune condition which can impair walking ability. Atlas5D began working with Biogen and the Massachusetts General Hospital to engage people with MS, who helped to test the technology in their homes. Publications are in progress, with expected release dates across 2016-2017.

“The Echo5D solution is the first of its kind in the world to gather accurate real-world data for MS without requiring the patient to do anything: no sensors to wear, nothing to recharge. We are encouraged by the quality and context of the information. It’s like we’ve opened up a world of MS that was previously invisible. Our vision is to provide meaningful data about a patient’s mobility, which — by allowing us to understand MS in a way we couldn’t before — may ultimately lead to better outcomes.”

Glenn Phillips, PhD

Director, Health Economics and Outcomes Research, Biogen

Learn more about how Echo5D can help you with real-world data and insights for stroke, Parkinson’s, Alzheimer’s, arthritis, and many more conditions. Contact us now.